Skip to Content

Femara (letrozole) Disease Interactions

There are 3 disease interactions with Femara (letrozole):


Letrozole (Includes Femara) ↔ liver disease

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Letrozole is extensively metabolized by the liver. The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment. No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.


  1. "Product Information. Femara (letrozole)." Novartis Pharmaceuticals, East Hanover, NJ.

Letrozole (Includes Femara) ↔ cholesterol

Moderate Potential Hazard, Moderate plausibility. Applies to: Hyperlipidemia

In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients. CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients. Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%). Caution is recommended when prescribing letrozole to these patients. Consideration should be given to monitoring serum cholesterol.


Letrozole (Includes Femara) ↔ osteoporosis

Moderate Potential Hazard, Moderate plausibility. Applies to: Osteoporosis

Use of letrozole tablets may cause decreases in bone mineral density (BMD). Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis. Consider bone mineral density monitoring in patients treated with letrozole.

Femara (letrozole) drug interactions

There are 115 drug interactions with Femara (letrozole)

Femara (letrozole) alcohol/food interactions

There is 1 alcohol/food interaction with Femara (letrozole)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.